Auranofin
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Ridaura |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a685038 |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.047.077 |
| Chemical and physical data | |
| Formula | C20H35AuO9PS+ |
| Molar mass | 679.493 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Auranofin is a gold complex classified by the World Health Organization as an antirheumatic agent.
It has the brand name Ridaura.
Use in HIV infection
Auranofin is under investigation as means of reducing the viral reservoir of HIV that lies latent in the body's T-cells despite treatment with antiretroviral therapy. [2]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ Gold-based drug shows promise in clearing HIV reservoir in monkey study. Keith Alcorn. AIDSmaps.com. Accessed 23 April 2011.
See also
Further reading
- Jeon K, Byun M, Jue D (2003). "Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit". Exp Mol Med. 35 (2): 61–6. PMID 12754408.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Kim I, Jin J, Lee I, Park S (2004). "Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro". Br J Pharmacol. 142 (4): 749–55. doi:10.1038/sj.bjp.0705708. PMC 1575039. PMID 15159275.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Venardos K, Harrison G, Headrick J, Perkins A (2004). "Auranofin increases apoptosis and ischaemia-reperfusion injury in the rat isolated heart". Clin Exp Pharmacol Physiol. 31 (5–6): 289–94. doi:10.1111/j.1440-1681.2004.03993.x. PMID 15191400.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Hafejee A, Winhoven S, Coulson I (2004). "Jessner's lymphocytic infiltrate responding to oral auranofin". J Dermatolog Treat. 15 (5): 331–2. doi:10.1080/09546630410016924. PMID 15370403.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Rigobello M, Folda A, Baldoin M, Scutari G, Bindoli A (2005). "Effect of auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase". Free Radic Res. 39 (7): 687–95. doi:10.1080/10715760500135391. PMID 16036347.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Suarez-Almazor ME, Spooner CH, Belseck E, Shea B (2000). Suarez-Almazor, Maria E (ed.). "Auranofin versus placebo in rheumatoid arthritis". Cochrane Database Syst Rev (2): CD002048. doi:10.1002/14651858.CD002048. PMID 10796461.
{{cite journal}}: CS1 maint: multiple names: authors list (link)
External links
 | This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |